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Clinical question: What is the best approach to the treatment of drug-resistant tuberculosis 
(TB)?
Results: Evidence-based treatment of drug-susceptible TB is the best means of preventing 
the development of drug-resistant disease. Suspecting the possibility of drug-resistant TB, and 
prompt detection of all forms of drug-resistant TB, not only multidrug-resistant and extensively 
drug-resistant TB, should be part of the algorithm for diagnosis and management of all patients 
with active TB.
Implementation: Treatment of all forms of drug-resistant TB must be tailored to the specific 
form of resistance with appropriate and effective drug regimens.
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Introduction
Tuberculosis (TB) is a global pandemic, with 9.4 million incident cases   occurring in 
2009 and 1.7 million deaths attributed to the disease.1 In addition to the   worrisome   reality 
that the total number of cases globally is still increasing (although incidence rates are 
decreasing slightly), disease due to strains of Mycobacterium tuberculosis (MTB) that 
are resistant to treatment by first-line drugs is a serious threat to global TB control.
It is estimated that 17% of all new TB cases worldwide (population-weighted 
  proportion) harbor some form of drug resistance.2 The poorer outcomes and 
  complexities of treatment associated with drug-resistant disease make it necessary 
to promptly recognize, and adequately treat all forms of drug-resistant disease. The 
  objective of this review is to summarize the pathogenesis of drug-resistant TB, and 
use this understanding of pathogenesis, along with the best available published evidence 
to outline the key principles of prevention and treatment of drug-resistant TB.
Epidemiology and impact of drug-resistant TB
The World Health Organization (WHO) has estimated that 17% of all newly diagnosed 
patients with active TB have disease caused by drug-resistant strains. Of all TB patients, 
14.1% have either mono- or poly-drug resistance, over half of whom (7.4% of the global 
total) are resistant to isoniazid alone. Such forms of mono- and poly-resistant strains are 
seen in higher proportions in countries with high rates of MDR-TB.3 An estimated 2.9% 
of all new TB cases globally are multi-drug resistant (MDR-TB, defined as resistance to 
both isoniazid and rifampicin, the two most important first-line drugs). Less than 1% of 





as MDR-TB plus resistance to a second-line injectable drug 
and a fluoroquinolone). In twelve countries, 6% or more of 
new cases have MDR-TB, while 58 countries to date have 
reported at least one case of XDR-TB.2
Outcomes of treatment of drug-resistant TB are worse 
than drug-susceptible TB (DS-TB). The most extreme is 
XDR-TB – in the first reported outbreak of XDR-TB among 
HIV-infected individuals, all but one of 53 XDR-TB patients 
died of the disease, with a median survival of 16 days 
from the time the first sputum specimen was collected.4 
  However, a subsequent study from Peru reported that 29 
of 48 (60%) HIV-uninfected patients with XDR-TB were 
treated successfully.5
Outcomes of treatment of MDR-TB are somewhat better. 
Three systematic reviews estimated pooled success treatment 
rates of only 60%–70%, with failure rates of 10%–11%, 
  mortality of 10%–15%, and default rates of up to 20%.6–8 
Treatment of MDR-TB involves the use of second-line drugs 
that are less efficacious than first-line drugs, more   expensive, 
and have more adverse effects, making tolerance and 
  treatment adherence challenging. The cost of treatment 
from drugs alone is estimated to be 50–200 times higher 
for MDR-TB patients, compared with treatment of patients 
with drug-susceptible TB.9 An estimated 150,000 deaths were 
caused by MDR-TB in 2008, the majority because they were 
not treated with second-line drugs.9
The remaining and much more common forms of drug-
resistant TB have significantly worse outcomes than DS-TB, 
although cure rates with existing regimens are potentially 
higher than for MDR or XDR. A systematic review of studies 
of patients with strains that were isoniazid-resistant found 
significantly higher rates of failure, relapse, and acquired 
drug-resistance than in patients infected with strains that 
were susceptible to all drugs when treated with standardized 
regimens.3 Pooled failure and relapse rates were 10%–15% 
higher than among new cases with DS-TB.10 Outcomes were 
even worse among previously treated patients with isoniazid 
mono-resistance, in whom the combined failure and relapse 
rates ranged from 29% to 70% when treated with the WHO 
recommended standardized re-treatment regimen.10 A study 
of intermittent regimens among HIV-infected patients with 
TB found isoniazid mono-resistance to be the main risk factor 
for acquired rifamycin resistance.11
Pathogenesis of drug resistance – 
how does drug resistance develop?
In every 106 to 108 replications, wild strains of MTB undergo 
spontaneous mutations that confer resistance to a single drug; 
the average number of such spontaneous mutations to anti-TB 
drugs is shown in Table 1.12 When treated with a single drug, 
the population of TB bacilli initially shrinks due to the killing 
of susceptible organisms in the population, often rendering a 
person smear-negative (as a result of fewer organisms being 
present). However, the organisms that survive the initial phase 
are the drug-resistant mutants, and the proliferation of these 
mutants eventually causes the entire population of bacilli to 
be replaced by drug-resistant forms that continue to prolifer-
ate until they are numerous enough to cause recurrence of 
symptoms, and smear positivity; this is termed “the fall and 
rise phenomenon”.13
If treated with a single drug, and the bacillary load of the 
organisms exceeds 106, then emergence of strains that are 
resistant to that drug is almost certain. If the bacillary load 
exceeds 108 then resistance is likely to develop if only two 
drugs are used. Bacillary loads exceed 106 with tuberculous 
infiltrates alone (when sputum direct smears are negative 
although cultures are positive), and exceed 108 when cavities 
are present in patients with TB, at which time sputum direct 
smears are usually positive.14,15 One of the aims of modern 
anti-TB therapy is to prevent drug resistant mutants from 
proliferating. This is best accomplished by including at least 
three likely effective anti-tuberculous agents in the initial 
treatment regimen, as this will reduce the probability of 
emergence of drug resistance to 10-18 or lower.
During the initial phase of treatment the few mutants 
with spontaneous resistance to one drug will be killed more 
slowly than the “wild type” bacilli that are susceptible to all 
drugs. Hence during the first months of therapy these more 
resistant bacilli will survive longer. If therapy is interrupted 
early, through default, then these drug-resistant mutants will 
proliferate, increasing the proportion of drug-resistant forms, 
until this proportion becomes clinically significant. Low drug 
levels, either from malabsorption (as occurs in HIV-infected 
patients) or inadequate dosages of medications, will have the 
same effect. In the presence of isoniazid mono-resistance, for 
example, the use of the recommended two-drug therapy in the 
continuation phase of treatment is effectively rifampicin 
Table 1 Rates of spontaneous mutations conferring resistance to 
anti-TB drugs12,27
Drug Average mutation rate
Isoniazid 2.56 × 10-8
Rifampicin 2.25 × 10-10
Ethambutol 1 × 10-7
Streptomycin 2.95 × 10-8




Treatment of drug-resistant tuberculosis
monotherapy; this can explain the acquired rifamycin 
resistance observed in one recent trial with such patients,11 
and the poor outcomes observed when isoniazid-resistant 
patients are treated with standardized regimens.16
In summary, during treatment three possible mechanisms 
can result in the selection of drug-resistant mutant strains: 
treatment with an inadequate number of effective drugs, 
 sub-therapeutic dosing or absorption, or treatment interruption. 
Patient consumption of all doses of an appropriate drug regi-
men with the correct dosages is essential to prevent resistance. 
The value of evidence-based adequate drug regimens cannot 
be over-emphasized; unfortunately, these seem to be flouted 
in countries where drug regulatory systems are lax, and private 
physicians and pharmacies are allowed to prescribe drugs in 
an unregulated manner. For example, a study of the prescrip-
tions for TB among private practitioners in Mumbai, India, 
found that 106 practitioners prescribed 63 different regimens, 
only six of which were judged adequate.17 A study found that 
of the 20 countries with the highest MDR-TB prevalence, 
eleven had no adequate policies for sales and distribution of 
TB drugs. Regulation of rifampicin sales was also negatively 
correlated with the prevalence of MDR-TB.18 Controlling 
TB drugs at the national level and preventing their misuse, 
therefore, would be a key component to ensuring that TB 
patients receive appropriate treatment.
When should drug-resistant TB  
be suspected, and how should  
it be diagnosed?
The algorithm for the diagnosis of drug-resistant TB is 
founded on an understanding of the profile of TB patients 
who have a higher probability of harboring drug-resistant 
strains. This profile holds true for all forms of the disease, 
including paucibacillary (smear negative) forms.
Patients at risk of drug-resistant TB fall into three major 
groups: contacts of patients with drug-resistant TB, previously 
treated, and those who are failing therapy. Close contacts of 
patients with drug-resistant TB are more likely to have been 
infected with a resistant strain, and if they have active TB 
should be presumed to harbor a drug-resistant strain.19 Patients 
who have received TB treatment in the past include those who 
relapsed (have TB disease again after being declared “cured” in 
the past) and those who defaulted (did not complete a course of 
TB treatment as recommended in the past). Close to   one-third 
of all patients who default or relapse will have MDR-TB 
strains.16 It is therefore vital to obtain an accurate history of 
prior TB treatment as this is a very strong risk   factor for drug-
resistant TB.16 Up to 90% of all patients who fail treatment, 
defined as a positive AFB sputum smear or culture after 
5 months of therapy, will have MDR-TB strains.16 Given this, 
patients who remain smear positive after 3 months of treatment 
should be investigated for possible drug-resistant TB.20
The diagnosis of drug-resistant TB is made by performing 
drug-susceptibility testing (DST) of the strain of TB obtained 
from the patient. Patients who are at risk of drug-resistant TB 
based on the profiles mentioned above should be subjected 
to DST testing. Testing can be performed on traditional solid 
media such as Lowenstein-Jensen media, which is relatively 
inexpensive but requires 4–8 weeks for a result. DST using 
liquid media such as MGIT (Mycobacteria Growth Indicator 
Tube) provides results in 2–4 weeks, but is more expensive. 
Molecular methods, such as Xpert-Rif, can provide results 
within hours, but are the most expensive of all the currently 
available tests. A detailed description of these methods is 
beyond the scope of this article, but can be found at http:// 
www.tbevidence.org.
Principles of treatment of TB –  
how to prevent drug resistance
The broad objectives of anti-TB treatment are: (1) rapid 
reduction in bacillary load to reduce morbidity and mortality, 
and stop transmission, (2) prevent the emergence of drug-
resistant mutant strains, and (3) prevent relapse of disease.
To achieve objective 1, potent bactericidal drugs such 
as isoniazid, especially in the first week, and rifampicin are 
the most useful. To achieve the second objective, multiple 
drugs with proven (by DST) or likely (never previously used) 
efficacy are used, to prevent the selection of drug-resistant 
mutants as explained earlier. To achieve the third objective, 
treatment is prescribed for a sufficiently long duration, with 
monitoring of adherence to treatment, to eliminate residual 
surviving organisms that are responsible for disease relapse. 
The length of treatment with rifampicin plays an important 
role in achieving this third objective.21
Recommendations for the dosages, duration, and 
  combinations of drugs for treatment of drug-susceptible TB 
are based on sound evidence-based principles derived from 
multiple randomized trials.21 Adherence to authoritative 
guidelines for treatment22 and ensuring that all doses are 
taken correctly is unarguably the most effective means of 
preventing drug resistance.
Treatment of suspected  
drug-resistant TB
The “standardized” approach to treatment of suspected 





surveillance data. The advantage of such a standardized 
approach is that it prevents major errors in number, dosages, 
and duration of TB drugs.
The “empiric” approach, in contrast, takes into account 
the patient’s drug history, assuming the patient to be 
potentially resistant to the drugs that have been used in the 
past, thus tailoring treatment to the individual, at the risk 
of not using some of the drugs that the patient may still be 
susceptible to. This may then be modified if and when DST 
results are available.
The “individualized” treatment modifies the standardized 
or the empiric treatment to match treatment to individual drug 
susceptibility patterns once the results of a DST of the sputum 
culture are available. The choice of approach is dependent on 
available resources, but it is recommended that all patients 
have a DST immediately once resistance is suspected (based 
on the criteria listed above), and that empiric treatment for 
drug-resistant TB is commenced while awaiting the results 
of the DST.23
In the absence of a known contact with MDR-TB and 
when isoniazid mono-resistance is not suspected (based on 
population estimates of prevalence less than 4%), patients 
with active TB who have never before been treated should 
receive 6 months of rifampicin (R) and isoniazid (H), with 
pyrazinamide (Z) also prescribed in the initial 2 months of 
treatment (2HRZ/4HR).
Patients with active TB who had contact with a patient 
with documented drug-resistant TB should be started on 
treatment tailored to the susceptibility pattern of the source 
case, while awaiting the results of a DST on the strain of 
MTB isolated from the patient.
In new cases, but in areas where the prevalence of 
isoniazid resistance exceeds 10%, we recommend, treatment 
with an intensive phase of 2 months consisting of four 
drugs (H, R, Z, and Ethambutol (E), while the continuation 
phase should include ethambutol throughout, in addition to 
isoniazid and rifampicin, if DST are not available.1 If DST are 
available then initial empiric therapy should include HRZE 
until DST results are available.
In cases of different forms of suspected drug-resistant TB, 
the normal regimen should be commenced, which should then 
be individualized once results of a DST are available. In view 
of the increased number of drugs, the prolonged duration of 
treatment and the need to be aware of possible interactions 
and adverse drug reactions of second-line drugs, we recom-
mend the referral of patients with drug-resistant TB to TB 
specialists for treatment.
Treatment of confirmed  
drug-resistant TB
A great deal of writing about the management of 
drug-resistant TB has focused on the treatment of MDR-TB 
and more recently, XDR-TB. While these forms are known 
to have much worse outcomes than drug-susceptible TB,3 
failure to adequately treat other forms of mono- and poly-
resistant TB would be highly imprudent. Failure to treat 
patients with these patterns of resistance with adequate regi-
mens will lead to the development of MDR- and XDR-TB, 
with disastrous immediate consequences for the individual 
patients, and for TB control programs in the long term.24
Five broad groups of drugs used for the treatment of 
drug-resistant TB (in hierarchical order of importance and 
preference while designing a regimen), are listed in Table 4. 
The dosages of the most important, recommended second-
line drugs are detailed in Table 2.23
Isoniazid mono-resistance
The standard recommendation is 2 months Rifampin, 
Pyrazinamide plus Ethambutol, followed by 8 months 
Rifampin plus Ethambutol 2RZE+8RE. However this is of 
unproven efficacy. Given the evidence that treatment with 
standard regimens for new or previously treated cases is 
ineffective, as reviewed earlier, we do not recommend this. 
On the other hand moxifloxacin has been found in two stud-
ies to have equivalent efficacy as isoniazid when used along 
with RZE in TB patients with drug-susceptible strains.25,26 
Therefore we suggest, a substitution of isoniazid with a 
fluoroquinolone throughout treatment for isoniazid mono-
resistant active TB (Table 3).
Poly-drug resistance and other forms  
of mono-resistance
The many possible forms, each with specific treatment 
  recommendations, are summarized in Table 3. Note that 
many authorities recommend the same treatment for 
mono-Rif resistance as for MDR-TB.
MDR-TB
The treatment regimen for confirmed MDR-TB is tailored to 
the DST profile if available. However while awaiting DST, 
or if DST are not available, treatment principles include 
the initial use of at least four drugs that the patient should 
be susceptible to (likely effective), and including an injectable 
for at least 7 months, and at least three likely effective drugs 
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Table 2 Dosage, action and adverse reactions of first-line and selected second-line anti-TB drugs
Drug Daily dose and range (mg/kg body  
weight), maximum dose (mg)
Role in the treatment strategy Adverse reactions
Rifampicin 10 (8–12), 600 • Most important anti-TB drug • Hepatotoxicity
•   Bactericidal and sterilizing, rapidly  
rendering the patient non-infective
• Rash
• Hematologic
• Allows shortening of therapy to half
Isoniazid 5 (4–6), 300 • Bactericidal • Hepatotoxicity




Pyrazinamide 25 (20–30), 2000 • Bactericidal early effect
•   Allows shortening of therapy by  




Ethambutol 15 (15–20), 1600 • Bacteriostatic
•   The least effective drug, but  
protects against resistance
•   Optic neuritis  
(can cause blindness)
• Rash
Streptomycin 15, 1000 • Bactericidal • nephrotoxicity
• vestibular toxicity
• Ototoxicity
Kanamycin 15, 1000 • Bactericidal • nephrotoxicity
• vestibular toxicity
• Ototoxicity
Levofloxacin 750–1000 mg/day • Strong anti-TB activity • nausea
• Tremulousness, insomnia
• Arthralgias
•   Rare QTc prolongation, 
tendon rupture
Ethionamide 15 (15–20), 1000  
frequently divided
• Bacteriostatic •   Gastrointestinal upset  
and nausea
• Hepatotoxicity
•   Reversible  
hypothyroidism
Abbreviation: DS-TB, drug-susceptible TB.
Table 3 Regimens for the treatment of mono-resistant and poly-resistant strains28
Pattern of drug resistance Suggested regimen Minimum duration of treatment   
in months
H 2RZE and FQ followed by 4–7 R and FQ (FQ = 400 mg moxifloxacin  
or 750–1000 mg levofloxacin substituted for H in the standard  
treatment regimen)
6–9
R 2HZE and FQ followed by 10–16 HE and FQ ± injectable for the  
initial 6 months
12–18
H and Z RE and FQ 9–12 (longer if extensive disease)
H and E RZ and FQ 9–12 (longer if extensive disease)
R and E  
(±S)
HZ and FQ, plus injectable for at least the first 2–3 months  
(6 months if extensive disease)
18
R and Z  
(±S)
HE and FQ, plus injectable for at least the first 2–3 months  
(6 months if extensive disease)
18
H, E, Z  
(±S)
R and FQ, plus an oral second-line agent, plus injectable for  
at least the first 2–3 months (6 months if extensive disease)
18





this should include all drugs from Group 1 (pyrazinamide 
and ethambutol) to which the patient is susceptible, a 
second-line injectable (from Group 2), a later generation 
quinolone (moxifloxacin or levofloxacin – from Group 3), 
and additional drugs from groups 4 and 5 to complete an 
adequate regimen. Ethionamide/prothionamide appear to 
be the most effective of the Group 4 drugs. The injectable 
agent is prescribed for a minimum of 7 months, and ideally 
for at least 4 months beyond when the patient first becomes 
smear- or culture-negative.23
XDR-TB
The principles used for treatment, based on the study from 
Peru, which has reported the highest success rates to date, are 
similar to those used for the treatment of MDR-TB, with oral 
agents prescribed for at least 18 months and injectable drugs 
prescribed for at least 8 months beyond culture   conversion. 
In the Peru cohort, 14.6% of all patients underwent lung 
resection surgery as an adjunct to chemotherapy. Only eleven 
of the 48 patients needed hospitalization during treatment, 
highlighting the possibility of successful outpatient treatment 
of XDR-TB.5
Conclusion
The occurrence of rare, spontaneous mutations during 
replication of the TB bacillus is a natural phenomenon, but 
the preferential selection and propagation of such resistant 
mutants is man-made, and largely preventable. Regimens 
for drug-susceptible TB have a strong evidence base and, 
when employed in the right dosages for the right duration 
with close monitoring of adherence, lead to high cure rates 
without the development of drug-resistant strains. Getting 
treatment right the first time should therefore be the primary 
focus of TB control programs worldwide.
Detection of all forms of drug-resistance, not only MDR- 
and XDR-TB, should be an integral part of the diagnosis 
and management of all patients with active TB. Treatment 
of all forms of drug-resistant TB must be tailored to the 
specific form of resistance with appropriate and effective 
drug regimens.
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